

Florian Klein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7839585/publications.pdf>

Version: 2024-02-01

122
papers

14,194
citations

46918

47
h-index

23472

111
g-index

144
all docs

144
docs citations

144
times ranked

13528
citing authors

#	ARTICLE	IF	CITATIONS
1	Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding. <i>Science</i> , 2011, 333, 1633-1637.	6.0	1,046
2	Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. <i>Nature</i> , 2015, 522, 487-491.	13.7	665
3	Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. <i>Nature</i> , 2013, 503, 224-228.	13.7	593
4	Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization. <i>Cell</i> , 2013, 153, 126-138.	13.5	478
5	HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. <i>Nature</i> , 2012, 492, 118-122.	13.7	463
6	Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. <i>Lancet Regional Health - Europe</i> , The, 2021, 6, 100122.	3.0	452
7	COVID-19 associated pulmonary aspergillosis. <i>Mycoses</i> , 2020, 63, 528-534.	1.8	434
8	Antibodies in HIV-1 Vaccine Development and Therapy. <i>Science</i> , 2013, 341, 1199-1204.	6.0	433
9	Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. <i>Nature</i> , 2013, 503, 277-280.	13.7	424
10	Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity. <i>Cell</i> , 2014, 158, 1243-1253.	13.5	419
11	<scp>SARS</scp> â€CoVâ€2 targets neurons of 3D human brain organoids. <i>EMBO Journal</i> , 2020, 39, e106230.	3.5	401
12	HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. <i>Nature</i> , 2016, 535, 556-560.	13.7	400
13	Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. <i>Nature Medicine</i> , 2017, 23, 185-191.	15.2	399
14	HIV-1 Integration Landscape during Latent and Active Infection. <i>Cell</i> , 2015, 160, 420-432.	13.5	393
15	Combination therapy with anti-HIV-1 antibodies maintains viral suppression. <i>Nature</i> , 2018, 561, 479-484.	13.7	392
16	Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design. <i>Science</i> , 2011, 334, 1289-1293.	6.0	345
17	mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. <i>Nature Medicine</i> , 2022, 28, 477-480.	15.2	342
18	Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice. <i>Cell</i> , 2014, 158, 989-999.	13.5	337

#	ARTICLE	IF	CITATIONS
19	Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy. <i>Cell</i> , 2014, 156, 633-648.	13.5	318
20	Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. <i>Cell</i> , 2020, 182, 843-854.e12.	13.5	310
21	Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. <i>Journal of Experimental Medicine</i> , 2014, 211, 2061-2074.	4.2	297
22	A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. <i>Nature</i> , 2016, 533, 105-109.	13.7	281
23	Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1255-1265.	5.2	279
24	HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. <i>Science</i> , 2016, 352, 997-1001.	6.0	263
25	HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 16538-16543.	3.3	247
26	Early antibody therapy can induce long-lasting immunity to SHIV. <i>Nature</i> , 2017, 543, 559-563.	13.7	244
27	Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. <i>Nature Medicine</i> , 2018, 24, 1701-1707.	15.2	195
28	Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. <i>Nature Medicine</i> , 2019, 25, 547-553.	15.2	191
29	Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. <i>Journal of Experimental Medicine</i> , 2012, 209, 1469-1479.	4.2	156
30	Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans. <i>Cell Host and Microbe</i> , 2021, 29, 917-929.e4.	5.1	132
31	Olfactory and Gustatory Dysfunction in Coronavirus Disease 2019 (COVID-19). <i>Clinical Infectious Diseases</i> , 2020, 71, 2262-2264.	2.9	127
32	Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. <i>Nature Medicine</i> , 2020, 26, 222-227.	15.2	108
33	Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 10598-10603.	3.3	106
34	Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody. <i>Cell</i> , 2020, 180, 471-489.e22.	13.5	106
35	Long-lived macrophage reprogramming drives spike protein-mediated inflammasome activation in COVID-19. <i>EMBO Molecular Medicine</i> , 2021, 13, e14150.	3.3	98
36	Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV. <i>Nature Medicine</i> , 2019, 25, 1589-1600.	15.2	92

#	ARTICLE	IF	CITATIONS
37	Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike. <i>Nature Communications</i> , 2015, 6, 8167.	5.8	87
38	Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies. <i>Journal of Experimental Medicine</i> , 2013, 210, 1235-1249.	4.2	85
39	Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. <i>Immunity</i> , 2019, 50, 1513-1529.e9.	6.6	85
40	Innovations, challenges, and minimal information for standardization of humanized mice. <i>EMBO Molecular Medicine</i> , 2020, 12, e8662.	3.3	82
41	Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. <i>Journal of Experimental Medicine</i> , 2014, 211, 2361-2372.	4.2	79
42	A mouse model for HIV-1 entry. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 15859-15864.	3.3	75
43	Antibody-mediated neutralization of SARS-CoV-2. <i>Immunity</i> , 2022, 55, 925-944.	6.6	74
44	Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy. <i>New England Journal of Medicine</i> , 2016, 375, 2019-2021.	13.9	66
45	Relationship between intact HIV-1 proviruses in circulating CD4 ⁺ T cells and rebound viruses emerging during treatment interruption. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E11341-E11348.	3.3	65
46	Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers. <i>Lancet Respiratory Medicine</i> , 2021, 9, e104-e105.	5.2	65
47	Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness. <i>Journal of Experimental Medicine</i> , 2010, 207, 1995-2002.	4.2	62
48	Rapid SARS-CoV-2 testing in primary material based on a novel multiplex RT-LAMP assay. <i>PLoS ONE</i> , 2020, 15, e0238612.	1.1	58
49	Evaluation of a Rapid Antigen Test To Detect SARS-CoV-2 Infection and Identify Potentially Infectious Individuals. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0089621.	1.8	55
50	Antibody-mediated prevention and treatment of HIV-1 infection. <i>Retrovirology</i> , 2018, 15, 73.	0.9	53
51	RNAemia Corresponds to Disease Severity and Antibody Response in Hospitalized COVID-19 Patients. <i>Viruses</i> , 2020, 12, 1045.	1.5	53
52	Sensitivity of anti-SARS-CoV-2 serological assays in a high-prevalence setting. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1063-1071.	1.3	50
53	A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo. <i>PLoS Pathogens</i> , 2015, 11, e1005238.	2.1	43
54	Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers. <i>Cell Host and Microbe</i> , 2022, 30, 69-82.e10.	5.1	42

#	ARTICLE	IF	CITATIONS
55	Broadly Neutralizing Antibodies Developed by an HIV-Positive Elite Neutralizer Exact a Replication Fitness Cost on the Contemporaneous Virus. <i>Journal of Virology</i> , 2012, 86, 12676-12685.	1.5	40
56	CD86+ Antigen-Presenting B Cells Are Increased in Cancer, Localize in Tertiary Lymphoid Structures, and Induce Specific T-cell Responses. <i>Cancer Immunology Research</i> , 2021, 9, 1098-1108.	1.6	38
57	openPrimeR for multiplex amplification of highly diverse templates. <i>Journal of Immunological Methods</i> , 2020, 480, 112752.	0.6	36
58	First manifestation of adult-onset Still's disease after COVID-19. <i>Lancet Rheumatology</i> , The, 2021, 3, e319-e321.	2.2	36
59	Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 1498.	1.5	33
60	Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial. <i>Lancet Microbe</i> , The, 2022, 3, e203-e214.	3.4	33
61	A missing link between SARS-CoV-2 and the eye?: ACE2 expression on the ocular surface. <i>Journal of Medical Virology</i> , 2021, 93, 78-79.	2.5	31
62	Cerebrospinal Fluid Analysis Post-COVID-19 Is Not Suggestive of Persistent Central Nervous System Infection. <i>Annals of Neurology</i> , 2022, 91, 150-157.	2.8	30
63	Effective high-throughput isolation of fully human antibodies targeting infectious pathogens. <i>Nature Protocols</i> , 2021, 16, 3639-3671.	5.5	29
64	Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike protein-specific antibodies. <i>Journal of Immunological Methods</i> , 2021, 490, 112958.	0.6	28
65	Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 445-446.	4.6	28
66	Structural Basis for a Convergent Immune Response against Ebola Virus. <i>Cell Host and Microbe</i> , 2020, 27, 418-427.e4.	5.1	25
67	More than loss of taste and smell: burning watering eyes in coronavirus disease 2019. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1560.e5-1560.e8.	2.8	23
68	The Alpha Variant (B.1.1.7) of SARS-CoV-2 in Children: First Experience from 3544 Nucleic Acid Amplification Tests in a Cohort of Children in Germany. <i>Viruses</i> , 2021, 13, 1600.	1.5	23
69	SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia. <i>Leukemia</i> , 2022, 36, 562-565.	3.3	23
70	TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes. <i>EBioMedicine</i> , 2019, 45, 328-340.	2.7	22
71	Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG. <i>Microorganisms</i> , 2021, 9, 733.	1.6	22
72	Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization. <i>Immunity</i> , 2022, 55, 341-354.e7.	6.6	21

#	ARTICLE	IF	CITATIONS
73	Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants. <i>Journal of Hepatology</i> , 2019, 70, 593-602.	1.8	20
74	Detection of SARS-CoV-2 viremia before onset of COVID-19 symptoms in an allo-transplanted patient with acute leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 716-719.	1.3	20
75	SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 960-971.	0.9	20
76	Exploiting B Cell Receptor Analyses to Inform on HIV-1 Vaccination Strategies. <i>Vaccines</i> , 2020, 8, 13.	2.1	18
77	HIV infection of CD4 T cells impairs antigen-specific B cell function. <i>EMBO Journal</i> , 2020, 39, e105594.	3.5	18
78	Rapid response infrastructure for pandemic preparedness in a tertiary care hospital: lessons learned from the COVID-19 outbreak in Cologne, Germany, February to March 2020. <i>Eurosurveillance</i> , 2020, 25, .	3.9	18
79	LIN28B enhanced tumorigenesis in an autochthonous KRASG12V-driven lung carcinoma mouse model. <i>Oncogene</i> , 2018, 37, 2746-2756.	2.6	16
80	Repertoire characterization and validation of gB-specific human IgGs directly cloned from humanized mice vaccinated with dendritic cells and protected against HCMV. <i>PLoS Pathogens</i> , 2020, 16, e1008560.	2.1	16
81	Venous blood gas analysis in patients with COVID-19 symptoms in the early assessment of virus positivity. <i>Journal of Laboratory Medicine</i> , 2021, 45, 27-30.	1.1	16
82	Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies. <i>Gut</i> , 2021, 70, 1734-1745.	6.1	15
83	Immune Responses to SARS-CoV-2 Infection and Vaccination in Dialysis Patients and Kidney Transplant Recipients. <i>Microorganisms</i> , 2022, 10, 4.	1.6	15
84	Predicting in vivo escape dynamics of HIV-1 from a broadly neutralizing antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	14
85	Effective high-throughput RT-qPCR screening for SARS-CoV-2 infections in children. <i>Nature Communications</i> , 2022, 13, .	5.8	14
86	No secret hiding place? Absence of SARS-CoV-2 on the ocular surface of 1145 hospitalized patients in a pandemic area. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2021, 259, 1605-1608.	1.0	13
87	Progress in HIV-1 antibody research using humanized mice. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 285-293.	1.5	12
88	Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections. <i>Emerging Infectious Diseases</i> , 2022, 28, 1050-1052.	2.0	11
89	COVID-19 complicated by parainfluenza co-infection in a patient with chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2020, 105, 508-511.	1.1	10
90	Morbidity of Respiratory Syncytial Virus (RSV) Infections: RSV Compared With Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Children Aged 0-4 Years in Cologne, Germany. <i>Journal of Infectious Diseases</i> , 2022, 226, 2050-2053.	1.9	10

#	ARTICLE	IF	CITATIONS
91	Determining the reliability of rapid SARS-CoV-2 antigen detection in fully vaccinated individuals. <i>Journal of Clinical Virology</i> , 2022, 148, 105119.	1.6	10
92	Opening Fronts in HIV Vaccine Development: Tracking the development of broadly neutralizing antibodies. <i>Nature Medicine</i> , 2014, 20, 478-479.	15.2	9
93	Epitopes of Naturally Acquired and Vaccine-Induced Anti-Ebola Virus Glycoprotein Antibodies in Single Amino Acid Resolution. <i>Biotechnology Journal</i> , 2020, 15, 2000069.	1.8	9
94	Safe and effective pool testing for SARS-CoV-2 detection. <i>Journal of Clinical Virology</i> , 2021, 145, 105018.	1.6	9
95	Isolation of HIV-1-reactive antibodies using cell surface-expressed gp160 ^{tr} cBaL. <i>Journal of Immunological Methods</i> , 2013, 397, 47-54.	0.6	8
96	Lactobacilli Expressing Broadly Neutralizing Nanobodies against HIV-1 as Potential Vectors for HIV-1 Prophylaxis?. <i>Vaccines</i> , 2020, 8, 758.	2.1	8
97	SARS-CoV-2 Infection in Fully Vaccinated Individuals of Old Age Strongly Boosts the Humoral Immune Response. <i>Frontiers in Medicine</i> , 2021, 8, 746644.	1.2	8
98	SARS-CoV-2 neutralizing antibody treatment in patients with COVID-19 and immunodeficiency due to B-cell non-Hodgkin lymphoma. <i>Blood Advances</i> , 2022, 6, 1580-1584.	2.5	8
99	No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults. <i>IScience</i> , 2022, 25, 103951.	1.9	8
100	Reply to Gourtsoyannis. <i>Clinical Infectious Diseases</i> , 2020, 71, 3018-3019.	2.9	6
101	COVID-19 study found that 0.4% of 5730 asymptomatic children aged 0-18 years tested positive for virus before hospital procedures or admission. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2021, 110, 2584-2585.	0.7	6
102	Protocol of the Cologne Corona Surveillance (CoCoS) Study- a prospective population-based cohort study. <i>BMC Public Health</i> , 2021, 21, 1295.	1.2	6
103	Mobile PCR-based surveillance for SARS-CoV-2 to reduce visiting restrictions in nursing homes during the COVID-19 pandemic: a pilot study. <i>Infection</i> , 2022, 50, 607-616.	2.3	5
104	Modeling the Amplification of Immunoglobulins through Machine Learning on Sequence-Specific Features. <i>Scientific Reports</i> , 2019, 9, 10748.	1.6	4
105	CD34 ⁺ Humanized Mouse Model to Study Mucosal HIV-1 Transmission and Prevention. <i>Vaccines</i> , 2021, 9, 198.	2.1	4
106	Safe and Effective Pool Testing for SARS-CoV-2 Detection. <i>SSRN Electronic Journal</i> , 0, , .	0.4	4
107	CXCR3 Expression Pattern on CD4 ⁺ T Cells and IP-10 Levels with Regard to the HIV-1 Reservoir in the Gut-Associated Lymphatic Tissue. <i>Pathogens</i> , 2022, 11, 483.	1.2	4
108	Antibody response after COVID-19 vaccination in intravenous immunoglobulin-treated immune neuropathies. <i>European Journal of Neurology</i> , 2022, 29, 3380-3388.	1.7	4

#	ARTICLE	IF	CITATIONS
109	Contact-dependent inhibition of HIV-1 replication in ex vivo human tonsil cultures by polymorphonuclear neutrophils. <i>Cell Reports Medicine</i> , 2021, 2, 100317.	3.3	3
110	Case Report: Clinical Management of a Patient With Metastatic Non-Small Cell Lung Cancer Newly Receiving Immune Checkpoint Inhibition During Symptomatic COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 798276.	2.2	3
111	Engineering Antibodies to Enhance Activity and Increase Half-life. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A210-A210.	0.5	2
112	HEnRY: a DZIF LIMS tool for the collection and documentation of biomaterials in multicentre studies. <i>BMC Bioinformatics</i> , 2020, 21, 290.	1.2	2
113	Antibody Teamwork against Ebola Virus Disease. <i>Immunity</i> , 2020, 52, 217-219.	6.6	0
114	Transcriptome analysis of reactivated T H 1 cells reveal distinct differences between priming and reactivation processes. <i>FASEB Journal</i> , 2021, 35, .	0.2	0
115	Title is missing!. , 2020, 16, e1008560.		0
116	Title is missing!. , 2020, 16, e1008560.		0
117	Title is missing!. , 2020, 16, e1008560.		0
118	Title is missing!. , 2020, 16, e1008560.		0
119	Title is missing!. , 2020, 16, e1008560.		0
120	Title is missing!. , 2020, 16, e1008560.		0
121	Title is missing!. , 2020, 16, e1008560.		0
122	Title is missing!. , 2020, 16, e1008560.		0